COPENHAGEN, Denmark, December 9, 2013 /PRNewswire/ --
Investment will Aid Atonomics in Development of an Advanced Platform for Testing of Lifestyle Diseases
Atonomics announces today that it has entered into an agreement with Omron Healthcare, which will enable Atonomics to advance the development of the Atolyzer®Consumer device for advanced diagnostic testing of lifestyle diseases in a consumer pharmacy setting. As part of the transaction Omron Healthcare is taking a minority equity stake in Atonomics.
The Atolyzer®Consumer device is the initial product line under the Atolyzer®Platform, a fully integrated immuno-, metabolic-, and molecular diagnostic platform, designed to deliver central laboratory performance in a near-patient environment. The platform consists of three devices currently under development: Atolyzer®Consumer, Atolyzer®PoC and Atolyzer®Gene.
Atonomics is targeting to create a paradigm shift in how lifestyle diseases are managed today. "We want to change the way people are going to controls at the GP office for a yearly check-up of their type-2 diabetes or heart problem to be able in the future additionally to monitor and manage their disease status actively towards less disease complications and simply a better quality of life," says Thomas Warthoe, Atonomics' CEO.
"The Atolyzer®Consumer device combines small size, ease of use, portability and low cost in a system that is based on well-established chemistries, reagents, and technologies. We look forward to assisting Atonomics in moving this technology towards commercialization," says Kiichiro Miyata, President and CEO of Omron Healthcare.
This collaboration re-emphasizes the development pathway that Atonomics has embarked upon, and duly stresses the need to offer cost effective
|SOURCE Atonomics A/S|
Copyright©2012 PR Newswire.
All rights reserved